Clinical trials
Oropharyngeal Squamous Cell Carcinoma clinical trials
Below are recruiting oropharyngeal squamous cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 126 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06741982RecruitingPhase 1
Immune-targeted therapy and virus treatment before head and neck cancer surgery
This trial tests a combination of immune therapy, targeted drugs, and a virus-based treatment before surgery for head and neck cancer that has spread to lymph nodes. The goal is to see if this approach can shrink the tumor and improve outcomes.
Chengdu, SichuanAges 18–70 - NCT06984861RecruitingPhase 2
Reduced radiation with chemo for HPV-related throat cancer
This trial tests if giving less radiation along with chemotherapy is safe and effective for people with HPV-positive throat cancer. It aims to reduce side effects while still controlling the cancer.
Basking Ridge, New JerseyAges 18 years+ - NCT06305676Recruiting
A study for early detection of HPV throat cancer
This study looks for early signs of HPV-related throat cancer. If you've just been diagnosed and haven't started treatment, your blood or saliva samples may help improve future screening tests.
Tampa, FloridaAges 18 years+ - NCT06007092RecruitingPhase 1/Phase 2
HPV vaccine trial for oropharyngeal cancer patients
This trial tests a therapeutic vaccine for people with HPV16-positive oropharyngeal cancer who have finished curative treatment and are free of disease. The vaccine aims to help the immune system prevent the cancer from coming back.
VillejuifAges 18 years+ - NCT05865028RecruitingPhase 2
Test drug APG-157 for abnormal mouth tissue
This Phase 2 trial studies whether APG-157 can safely improve abnormal cells in the mouth (dysplasia) or early cancer-like changes (carcinoma in situ). You may be eligible if you have a visible, biopsy-proven lesion and can take oral medication while meeting blood and health requirements.
Miami, FloridaAges 18 years+ - NCT04277858RecruitingPhase 2
Pre-surgery chemo plus robotic surgery for p16-positive throat cancer
This trial tests whether giving chemotherapy before robotic surgery works well for certain p16-positive oropharyngeal (throat) cancers. It aims to shrink or control the cancer and allow the surgeon to remove the tumor with clean margins while avoiding cancer spread beyond the neck.
Montreal, QuebecAges 18–80
Hear when a new Oropharyngeal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for oropharyngeal squamous cell carcinoma?
- Yes. Clin2 currently lists 126 recruiting oropharyngeal squamous cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a oropharyngeal squamous cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a oropharyngeal squamous cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Recurrent Oropharyngeal Squamous Cell Carcinoma
- Metastatic Oropharyngeal Squamous Cell Carcinoma
- Oropharyngeal Squamous Cell Carcinoma (SCC)
- Head and Neck Squamous Cell Carcinoma
- Esophageal Squamous Cell Carcinoma
- Squamous Cell Carcinoma
- Clear Cell Renal Cell Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.